Effects of vitamin D analog, 22-oxa-1,25-dihydroxyvitamin D(3), on bone reconstruction by vascularized bone allograft.
We previously reported that vascularized bone allograft using immunosuppressants, such as cyclosporine A (CsA), is one approach for reconstruction of large bone defects in both experimental animals (Microsurgery 15:663; 1994) and clinically in humans (Lancet 347:970, 1996). Because immunosuppressive agents such as CsA induce significant side effects, including bone loss, other therapeutic agents supporting successful vascularized bone allografts have been sought after. We investigated the effects of 22-oxa-1,25-dihydroxyvitamin D(3) (OCT) on vascularized bone allograft, and compared its effects with CsA. Twelve-week-old DA rats with the major histocompatibility antigen (MHC) RT-1(a) were used as donors and age-matched Lewis rats with MHC RT-1(l) used as recipients. Allografted bones in rats treated with vehicle were rejected completely. Soft X-ray examination demonstrated that administration of OCT (0.5 microg/kg per day) for 12 weeks after bone graft induced bone union as effective as treatment for 12 weeks with CsA (10 mg/kg per day). Transplanted bones in OCT-treated rats showed higher bone mineral density than that in CsA-treated rats. Histologically, transplanted bones in OCT-treated rats at 12 weeks were nonvital, but these bones united with recipient vital bones. After cessation of 12 week treatment with OCT, new bone formation occurred around the grafted nonvital bones during a 9 month period. Transplanted bones in CsA-treated rats were vital and formed union with recipient bones, whereas cortical bones became thin when compared with nonvital bones in OCT-treated rats. Urinary deoxypyridinoline levels in rats treated with CsA were significantly higher than levels in rats treated with OCT, suggesting accelerated bone resorption in CsA-treated rats. These results suggest that OCT exerts an anabolic action on bone reconstruction by allogeneic bone transplantation.
Merida
L
L
Department of Orthopedic Surgery, Yamaguchi University School of Medicine, Yamaguchi, Japan.
Shigetomi
M
M
Ihara
K
K
Tsubone
T
T
Ikeda
K
K
Yamaguchi
A
A
Sugiyama
T
T
Kawai
S
S
D000596:Amino Acids / Q000652:urine; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016025:Bone Transplantation; D001864:Bone Wires; D002117:Calcitriol / Q000031:analogs & derivatives / Q000494:pharmacology*; D002118:Calcium / Q000097:blood; D016572:Cyclosporine / Q000494:pharmacology; D005360:Fibula / Q000098:blood supply / Q000473:pathology / Q000637:transplantation; D006085:Graft Survival / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D010758:Phosphorus / Q000097:blood; D051381:Rats; D011917:Rats, Inbred Lew; D013977:Tibia / Q000098:blood supply / Q000473:pathology / Q000637:transplantation*; D014184:Transplantation, Homologous
D000596:Amino Acids; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D010758:Phosphorus; D016572:Cyclosporine; C036020:deoxypyridinoline; D002117:Calcitriol; C051883:maxacalcitol; D002118:Calcium